Jerry Williamson has been named CEO of NanoView Biosciences. Williamson succeeds David Freedman, Ph.D., co-founder of NanoView, who will remain with the company as chief operating officer. Most recently, Williamson was president and CEO of KEW Inc. Prior to KEW, he was president and CEO of Metamark Genetics Inc. Williamson has held positions of senior leadership for Flagship Ventures; Genetix Ltd.; Biacore Inc.; and Pyrosequencing Inc. He received a B.S. degree in biochemistry from the University of Vermont and holds an MBA degree from Boston University.
Richard Klinghoffer, Ph.D., was named CEO of Presage Biosciences. Dr. Klinghoffer takes over CEO responsibilities from Nathan Caffo, who continues to advise the company on business and strategic matters as senior corporate advisor. Dr. Klinghoffer was chief scientific officer of Presage.
Agenus Inc. has appointed I-O drug development experts into key leadership positions. Sunil Gupta, M.D., joins Agenus as VP of Regulatory and Pharmacovigilance. Dr. Gupta is a trained oncologist with nearly 30 years in senior leadership positions in clinical development and regulatory affairs. He comes to Agenus from Sanofi where he had a distinguished career for 22 years including leading the approval process of cemiplimab (anti-PD-1), iniparib (PARP inhibition), oxaliplatin, and Taxotere.
Anna Wijatyk, M.D., joins Agenus as the VP of clinical development from Shire, where she was the VP oncology and global development lead in hematologic cancers. Dr. Wijatyk is a clinician who brings with her more than 20 years of experience in leadership positions at Bristol-Myers Squibb Co., Baxter, and Shire plc in oncology and rare diseases leading to approvals of products with the FDA, EMA, and Health Canada.
Neil Belloff has been appointed executive VP, general counsel, and corporate secretary of Eloxx Pharmaceuticals Inc. Belloff joins Eloxx from Celgene Corp., where he served as senior corporate counsel since 2011. He has more than 30 years of legal and business experience, with significant management and project development responsibilities in business critical areas including risk assessment, strategic planning, regulatory compliance, mergers and acquisitions, capital formation, privacy, pharmaceutical development, and securities matters. He is also a corporate governance and compliance expert.
Anupama S. Hoey is now chief business officer of Second Genome Inc. Hoey is leading all corporate development activities and strategic alliance opportunities for the company. Before joining Second Genome, Hoey served as chief business officer at Invenra Inc., where she successfully executed multiple high-profile deals with pharma companies and leading academic institutions. Before that, she served as VP of business development at Arcus Biosciences Inc., and as senior director of business development at Sutro Biopharma Inc.. Hoey earned a master of business administration degree from the University of San Francisco, a master of science degree in molecular virology and genetics from Case Western Reserve University, and a bachelor’s degree from Ohio State University.
David Moriarty, Ph.D., has become VP of development operations at Spruce Biosciences Inc. Before joining Spruce, Dr. Moriarty served as VP of clinical operations and data management at Jazz Pharmaceuticals Inc., where he assembled a successful clinical operations, data management and strategic outsourcing team delivering multiple submissions in hematology/oncology and sleep medicine, leading to approvals for Defitelio and Vxyeos. Before Jazz, he was responsible for leading clinical operations in different Janssen Pharmaceutical Alzheimer’s disease late development clinical programs over several years. At Tibotec Therapeutics, he held clinical operations roles leading to the approved HIV therapies of Prezista and Edurant. Dr. Moriarty also previously held positions of increasing responsibility at PPD, a global CRO, working primarily on the late development work of Humira for Abbott Pharmaceuticals. Dr. Moriarty earned a B.Sc. in Neuroscience from the University of Central Lancashire and a Ph.D. in Neuroscience from the University of Manchester.
Lynn C. Gold, Ph.D., has joined Impel NeuroPharma Inc. as senior VP of regulatory affairs. Dr. Gold has extensive oversight of regulatory strategy, agency communication, and regulatory submissions. Her prior appointments include Camargo Pharmaceutical Services LLC, where she was VP of scientific and regulatory affairs, and Sonus Pharmaceuticals Inc., where Dr. Gold served as VP of research and process development.
Sara Bonstein is now chief financial officer and chief operating officer of OncoSec Medical Inc. She joins OncoSec from Advaxis Inc. and also held key financial leadership positions with Eli Lilly, ImClone Systems and J&J.
BrainStorm Cell Therapeutics Inc. appointed Joseph Petroziello as VP of scientific & corporate communications and Susan Ward, Ph.D., as head of clinical operations. BrainStorm Cell Therapeutics is a leading developer of adult stem cell therapeutics for neurodegenerative diseases.